A Phase 3, Open label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13 [EXTENSTION OF 700033114]
Latest Information Update: 26 Apr 2016
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary) ; MMR-varicella zoster virus vaccine
- Indications Chickenpox; Measles; Meningococcal group B infections; Mumps; Rubella
- Focus Pharmacodynamics; Registrational
- Sponsors Novartis Vaccines
- 12 Apr 2016 Results (pooled analysis of this and other three studies) assessing whether pooled-sera hSBA titres predict individual seroprotection published in the Vaccine.
- 05 Mar 2015 New source identified and integrated (ClinicalTrials.gov record: NCT00847145)
- 21 Jan 2013 New trial record